OTCPK:PXMB.F

Stock Analysis Report

Executive Summary

Paxman AB (publ), together with its subsidiaries, develops and sells PAXMAN scalp cooling system for minimizing hair loss in connection with chemotherapy treatment in Europe, North-and South America, Asia, and Australia.

Snowflake

Fundamentals

Worrying balance sheet with weak fundamentals.

Risks

  • Paxman is not covered by any analysts.

Share Price & News

How has Paxman's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

PXMB.F

0.7%

US Medical Equipment

-0.2%

US Market


1 Year Return

n/a

PXMB.F

9.5%

US Medical Equipment

1.1%

US Market

No trading data on PXMB.F.

No trading data on PXMB.F.


Share holder returns

PXMB.FIndustryMarket
7 Day0%0.7%-0.2%
30 Day0%0.1%2.5%
90 Day0%2.5%1.6%
1 Yearn/a10.4%9.5%3.4%1.1%
3 Yearn/a69.3%64.1%45.2%35.8%
5 Yearn/a138.0%110.9%62.6%44.8%

Price Volatility Vs. Market

How volatile is Paxman's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Paxman undervalued based on future cash flows and its price relative to the stock market?

44.92x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Paxman's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Paxman's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Paxman is loss making, we can't compare its value to the US Medical Equipment industry average.

Paxman is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Paxman, we can't assess if its growth is good value.


Price Based on Value of Assets

Paxman is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Paxman expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Paxman has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of PXMB.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Paxman's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Paxman performed over the past 5 years?

37.3%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Paxman does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare Paxman's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Paxman's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Paxman has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Paxman has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Paxman improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Paxman's financial position?


Financial Position Analysis

Paxman's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Paxman's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Paxman's level of debt (76.1%) compared to net worth is high (greater than 40%).

Unable to establish if Paxman's debt level has increased without past 5-year debt data.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 1.3x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Paxman has less than a year of cash runway based on current free cash flow.

Paxman has less than a year of cash runway if free cash flow continues to reduce at historical rates of -23.2% each year.


Next Steps

Dividend

What is Paxman's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Paxman's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Paxman's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Paxman has not reported any payouts.

Unable to verify if Paxman's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Paxman has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Paxman's salary, the management and board of directors tenure and is there insider trading?

2.6yrs

Average board tenure


CEO

Richard Paxman (36yo)

3.6yrs

Tenure

0

Mr. Richard Paxman has been the Chief Executive Officer of Paxman AB (publ) since December 20, 2016 and has been its Director since February 10, 2017. Mr. Paxman has extensive experience in global market d ...


Board Age and Tenure

2.6yrs

Average Tenure

60.5yo

Average Age

The average tenure for the Paxman board of directors is less than 3 years, this suggests a new board.


Insider Trading

Paxman individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Buykr27,79011 Jul 19
Cimon Enterprise AB
EntityCompany
Shares5,032
Max Pricekr5.52
Buykr27,73204 Jul 19
Cimon Enterprise AB
EntityCompany
Shares4,968
Max Pricekr5.58
Buykr592,82229 Jun 19
Cimon Enterprise AB
EntityCompany
Shares100,000
Max Pricekr5.93
Sellkr592,82229 Jun 19
Per-Anders Johansson
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares100,000
Max Pricekr5.93
Buykr41,78317 Jun 19
Cimon Enterprise AB
EntityCompany
Shares7,764
Max Pricekr5.38
Buykr3,10128 May 19
Cimon Enterprise AB
EntityCompany
Shares499
Max Pricekr6.21
Buykr21,00928 May 19
Nomic AB
EntityCompany
Shares3,357
Max Pricekr6.26
Buykr6,94412 Mar 19
Nomic AB
EntityCompany
Shares2,614
Max Pricekr2.66
Buykr413,28108 Mar 19
Nomic AB
EntityCompany
Shares162,536
Max Pricekr2.54
Buykr313,34307 Mar 19
Nomic AB
EntityCompany
Shares127,820
Max Pricekr2.45

Ownership Breakdown


Management Team

  • Eva Jonasson (63yo)

    Chief Financial Officer

    • Tenure: 2.6yrs
  • Claire Paxman (41yo)

    Director of Sales & Training

    • Tenure: 0yrs
  • Kathryn Daniel (44yo)

    Export & Communications Manager

    • Tenure: 0yrs
  • Maria Escreet (49yo)

    Key Account Manager

    • Tenure: 0yrs
  • Patrick Burke (60yo)

    Technical & Engineering Manager

    • Tenure: 0yrs
  • Richard Paxman (36yo)

    CEO & Director

    • Tenure: 3.6yrs

Board Members

  • Per-Anders Johansson (65yo)

    Chairman of the Board

    • Tenure: 2.7yrs
  • Robert Kelly (58yo)

    Director

    • Tenure: 2.6yrs
  • Maria Bech (51yo)

    Director

    • Tenure: 2.6yrs
  • Björn Littorin (72yo)

    Director

    • Tenure: 2.7yrs
  • Glenn Paxman (63yo)

    Director

    • Tenure: 2.6yrs
  • Richard Paxman (36yo)

    CEO & Director

    • Tenure: 3.6yrs

Company Information

Paxman AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Paxman AB (publ)
  • Ticker: PXMB.F
  • Exchange: OTCPK
  • Founded: 1996
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr1.105b
  • Listing Market Cap: kr113.807m
  • Shares outstanding: 16.01m
  • Website: https://www.paxman.se

Number of Employees


Location

  • Paxman AB (publ)
  • Pirgatan 13
  • Karlshamn
  • Blekinge County
  • 374 35
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PAXOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKJun 2017
PXMB.FOTCPK (Pink Sheets LLC)YesShare CapitalUSUSDJun 2017

Biography

Paxman AB (publ), together with its subsidiaries, develops and sells PAXMAN scalp cooling system for minimizing hair loss in connection with chemotherapy treatment in Europe, North-and South America, Asia, ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/21 01:11
End of Day Share Price2019/05/23 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.